A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
Public ClinicalTrials.gov record NCT03138499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812)
Study identification
- NCT ID
- NCT03138499
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Brentuximab vedotin Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2017
- Primary completion
- Feb 21, 2021
- Completion
- Feb 21, 2021
- Last update posted
- Jan 9, 2024
2017 – 2021
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| UCLA Clinical and Translational Research Center (CTRC) | Los Angeles | California | 90095-1678 | — |
| Local Institution | Palo Alto | California | 94304 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University of California San Diego | San Diego | California | 92122 | — |
| Hartford Healthcare Cancer Institute at the Hospital of Central Connecticut | Plainville | Connecticut | 06062 | — |
| Orlando Health, Inc | Orlando | Florida | 32806 | — |
| Parkview Cancer Center | Fort Wayne | Indiana | 46845 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Tulane University Health Sciences Center | New Orleans | Louisiana | 70112 | — |
| Dana Farber/Harvard Cancer Center | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Bon Secours Saint Francis Cancer Center | Greenville | South Carolina | 29607 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37213 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| The University of Texas MD Anderson Cancer Center-merge | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03138499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03138499 live on ClinicalTrials.gov.